Advisers could pocket up to $100 million in fees from Johnson & Johnson’s $30 billion acquisition of Swiss biotech firm Actelion , the largest takeover of a European healthcare business in more than a decade. Four investment banks will share the advisory pot; J&J could cough up $30-$40 million in fees to its advisers, Lazard and Citi, while Actelion is expected to pay $45-$60 million to Bank of America and Credit Suisse, according to estimates from Thomson Reuters/Freeman Consulting.